Plano, Texas & New York – August 3, 2026
Integer Holdings Corporation, one of the world’s largest medical device contract development and manufacturing organizations (CDMOs), has entered into a definitive agreement to be acquired by KKR in an all-cash transaction valued at approximately US$5.7 billion. Under the agreement, Integer stockholders will receive US$127 per share in cash, representing a significant premium over the company’s historical trading price. The acquisition follows a comprehensive strategic review conducted by Integer’s Board of Directors and is expected to provide the company with additional long-term capital, expanded operational flexibility, and strategic resources to accelerate innovation, manufacturing capacity, and customer support. Upon completion of the transaction, Integer will become a privately held company while continuing to strengthen its position as a global manufacturing partner for leading medical device companies developing life-saving technologies. The acquisition reflects growing investor confidence in the expanding medical device outsourcing market and reinforces Integer’s importance within the global healthcare manufacturing ecosystem.
KKR Investment Strengthens Integer’s Global CDMO Platform
The definitive agreement represents one of the largest recent transactions involving a global medical device CDMO, highlighting the strategic value of Integer’s engineering expertise, manufacturing infrastructure and long-standing customer relationships. According to the agreement, KKR will finance the acquisition through a combination of equity investments and committed debt financing while supporting Integer’s long-term strategy of expanding manufacturing capacity, investing in advanced technologies and strengthening its highly skilled workforce. Company leadership emphasized that KKR’s deep healthcare experience and long-term investment philosophy make it an ideal strategic partner capable of accelerating future growth while preserving Integer’s customer-focused culture. KKR also plans to introduce a broad-based employee ownership and engagement program following completion of the transaction, reinforcing its commitment to long-term operational excellence and workforce development across its healthcare portfolio.
Strategic Acquisition Supports Innovation and Manufacturing Growth
Integer Holdings has established itself as one of the world’s leading medical device contract development and manufacturing organizations, serving global customers across high-growth therapeutic areas including cardio and vascular, neuromodulation, and cardiac rhythm management. The company’s engineering capabilities, manufacturing expertise and commitment to quality have positioned it as a trusted development and production partner for many of the medical technology industry’s leading innovators. Company executives noted that becoming a privately held organization will provide increased flexibility to pursue long-term investments in manufacturing expansion, technology development and operational capabilities without the pressures associated with public market reporting. The transaction also strengthens Integer’s ability to support customers developing increasingly sophisticated medical technologies while helping accelerate commercialization of life-saving healthcare products worldwide.
Advertisement
Transaction Advances Toward Regulatory and Shareholder Approval
The acquisition has received unanimous approval from Integer’s Board of Directors and now moves toward shareholder approval and customary regulatory clearances before completion, which is expected by the end of 2026. The transaction is not subject to a financing contingency, reflecting KKR’s strong financial commitment to the acquisition. Following closing, Integer’s common stock will no longer trade on the New York Stock Exchange, and the company will operate as a privately held business focused on delivering continued innovation across the global medical device sector. As demand for outsourced engineering, product development and advanced manufacturing continues to grow, the acquisition positions Integer to expand its capabilities while supporting customers developing next-generation cardiovascular, neuromodulation and other critical medical technologies. The agreement also underscores continued investment interest in the rapidly growing medical technology manufacturing industry, where specialized CDMOs play a central role in bringing innovative healthcare solutions to patients worldwide.
Source: Integer Holdings press release
